Table 2 Clinical characteristics of the patients with pseudolithiasis
From: Ceftriaxone-associated pseudolithiasis in hemodialysis patients: a case series study
Patient | Abdominal symptoms | Abnormalities in levels of transaminases/biliary enzymes | Dose of CTRX [g/day × duration (days)] | Dose of CTRX (mg/kg/day) | aDays to development | bDays to disappearance | Site | Treatment |
|---|---|---|---|---|---|---|---|---|
1 | − | −/− | 2 × 13 | 60.6 | 15 | −c | GB | − |
2 | − | +/− | 1 × 14 | 21.5 | 27 | 319 | GB | − |
3 | Vomiting | +/− | 1 × 14 | 21.6 | 35 | 78 | GB | Fasting |
4 | Nausea | −/+ | 1 × 14 | 16.0 | 36 | 117 | GB | Antibiotics |
5 | − | +/− | 1 × 9 (1× 8, 1 × 5, 1 × 11) | 17.9 | 25 | 168 | GB | Antibiotics |
6 | Appetite loss | +/+ | 1 × 14 | 21.0 | 14 | −c | GB | Fasting, antibiotics |
7 | Vomiting | −/− | 2 × 2, 1 × 6 | 13.1 | 19 | 20 | GB | Fasting, UDCA |
8 | Epigastralgia | +/+ | 1 × 11 (1 × 14) | 27.4 | 43 | 50 | GB, CBD | UDCA, antibiotics |
9 | Epigastralgia | −/− | 1 × 8 (1 × 3) | 22.7 | 21 | 37 | GB | UDCA |
10 | − | −/− | 1 × 7 | 18.7 | 8 | 39 | GB | − |
11 | − | −/− | 1 × 4 | 17.5 | 274 | 424 | GB | − |